The most common adverse effects of therapy with rosuvastatin and other statins are gastrointestinal disturbances. Other adverse effects reported include headache, skin rashes, dizziness, blurred vision, insomnia, dysgeusia. Reversible increases in serum-aminotransferase concentration may occur and liver function should be assessed before treatment is initiated and then monitored periodically until one year after the last elevation in dose. Hepatitis and pancreatitis have been reported. A hypersensitivity syndrome whose features have included angioedema has been reported. Myopathy, characterized by myalgia and muscle weakness and associated with increased creatinine phosphokinase concentration has been reported, especially in patients taking rosuvastatin concurrently with ciclosporin, fibric acid derivatives or nicotinic acid, rarely, rhabdomyolysis with acute renal failure may develop.